Omnigen in Acute Chemical Eye Injuries

Clinical Outcomes of Low Temperature Vacuum-dehydrated Amnion Membrane (Omnigen) in Treatment of Acute Chemical Eye Injuries

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05618522

Acronym

Omnigen

Enrollment

Registered

2022-11-16

Start date

2021-07-01

Completion date

2022-09-01

Last updated

2022-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Chemical Eye Injuries

Keywords

amniotic membrane, chemical eye injury

Brief summary

evaluation of the role of Omnigen in acute chemical eye injuries

Detailed description

prospective interventional study included patients with different degrees of acute chemical eye injuries were treated by Omnigen and followed up for one month

Interventions

PROCEDUREvacuum-dehydrated amnion membrane (omnigen)

applying the lens loaded with Omnigen on the cornea

DEVICEthe lens loaded with Omnigen

the lens loaded with Omnigen

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

prospective

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* acute chemical eye injury

Exclusion criteria

* absent or shallow fornices * symblepharon interfering with lens placement

Design outcomes

Primary

Measure	Time frame	Description
Epithelial healing	1 week	slit lamp examination with cobalt blue light after installing fluroscein drops
limbal ischaemia	1 week	slit lamp examination of the clock hours of vascularity around the limbususing both Due classification and Roper Hall

Secondary

Measure	Time frame	Description
omnigen tolerability	1 week	questionnaire for the patients asking about discomfort sensation or the need to patch the eye

Countries

Kuwait

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026